Jonathan Naft - Myomo General Manager - O&P
| MYO Stock | USD 5.07 0.12 2.42% |
Executive
Mr. Jonathan Naft is the General Manager OP at Myomo, Inc. He is the member of the OP community and is the founder of Geauga Rehabilitation Engineering, Inc. . He is a graduate of The Ohio State University College of Engineering and from Northwestern Universitys ProstheticOrthotic Center. For his Orthotic patients, he is experienced with cranial, upper extremity, lower extremity, and spinal. He is an examiner for the ABC certification exam and is a Past President for the Ohio Academy of Orthotists and Prosthetists. He is also a member of the prestigious AOPA Coding Committee, and was an invited speaker at several national prosthetic and orthotic conferences. He is on the advisory board for the OP Business news, and he routinely provides peer review throughout the industry.
| Address | 137 Portland Street, Boston, MA, United States, 02114 |
| Phone | 617 996 9058 |
| Web | https://myomo.com |
Jonathan Naft Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Naft against Myomo stock is an integral part of due diligence when investing in Myomo. Jonathan Naft insider activity provides valuable insight into whether Myomo is net buyers or sellers over its current business cycle. Note, Myomo insiders must abide by specific rules, including filing SEC forms every time they buy or sell Myomo'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Naft over a year ago Myomo exotic insider transaction detected |
Myomo Management Efficiency
The company has Return on Asset of (0.3145) % which means that on every $100 spent on assets, it lost $0.3145. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.8254) %, meaning that it generated no profit with money invested by stockholders. Myomo's management efficiency ratios could be used to measure how well Myomo manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of March 2025, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.85. At this time, Myomo's Net Tangible Assets are very stable compared to the past year. As of the 2nd of March 2025, Non Current Assets Total is likely to grow to about 1.1 M, while Total Assets are likely to drop about 10.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Paul Wotta | Nuwellis | 68 | |
| Michael Nketiah | Nexalin Technology | 48 | |
| FACC MBA | Nuwellis | N/A | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Jay Sturm | STRATA Skin Sciences | 69 | |
| John Gillings | STRATA Skin Sciences | N/A | |
| Kristine Williams | Rapid Micro Biosystems | N/A | |
| Nicholas DeGennaro | Vivos Therapeutics | N/A | |
| Sean Wirtjes | Rapid Micro Biosystems | 55 | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| Sandy Prietto | enVVeno Medical Corp | N/A | |
| Al Diaz | ReShape Lifesciences | N/A | |
| Robert Scott | Nuwellis | 45 | |
| Stephanie Huebner | Vivos Therapeutics | N/A | |
| David OBrien | SINTX Technologies | 59 | |
| Gregg Honigblum | SINTX Technologies | 62 | |
| Ryan Bock | SINTX Technologies | N/A | |
| Michael CFA | Rapid Micro Biosystems | N/A | |
| Ruth Hembree | Vivos Therapeutics | N/A | |
| Deina CPA | Bone Biologics Corp | 61 | |
| Shmuel Gov | STRATA Skin Sciences | 65 | |
Management Performance
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.31 |
Myomo Inc Leadership Team
Elected by the shareholders, the Myomo's board of directors comprises two types of representatives: Myomo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myomo. The board's role is to monitor Myomo's management team and ensure that shareholders' interests are well served. Myomo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myomo's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Gudonis, Chief Executive Officer, Director | ||
| Harry MD, Chief Officer | ||
| Joseph Chicoskie, Director Marketing | ||
| Colin Anderson, Global Operations | ||
| Galina Shtivelman, Senior Resources | ||
| David Henry, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | ||
| Fredrick Nahm, Medical Director | ||
| Steve Kelly, Founder, Chairman of the Board, President and Chief Operating Officer | ||
| Micah Mitchell, Chief Officer | ||
| Jonathan Naft, General Manager - O&P |
Myomo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myomo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (0.33) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 164.45 M | ||||
| Shares Outstanding | 33.7 M | ||||
| Shares Owned By Insiders | 5.19 % | ||||
| Shares Owned By Institutions | 60.34 % | ||||
| Number Of Shares Shorted | 702.03 K | ||||
| Price To Earning | (0.30) X |
Pair Trading with Myomo
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myomo position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myomo will appreciate offsetting losses from the drop in the long position's value.Moving against Myomo Stock
| 0.77 | BAX | Baxter International | PairCorr |
| 0.7 | CI | Cigna Corp | PairCorr |
| 0.55 | EDIT | Editas Medicine | PairCorr |
| 0.5 | ELV | Elevance Health | PairCorr |
| 0.33 | COO | Cooper Companies, | PairCorr |
The ability to find closely correlated positions to Myomo could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myomo when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myomo - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myomo Inc to buy it.
The correlation of Myomo is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myomo moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myomo Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myomo can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myomo Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myomo. If investors know Myomo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myomo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.23) | Revenue Per Share | Quarterly Revenue Growth 0.813 | Return On Assets | Return On Equity |
The market value of Myomo Inc is measured differently than its book value, which is the value of Myomo that is recorded on the company's balance sheet. Investors also form their own opinion of Myomo's value that differs from its market value or its book value, called intrinsic value, which is Myomo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myomo's market value can be influenced by many factors that don't directly affect Myomo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myomo's value and its price as these two are different measures arrived at by different means. Investors typically determine if Myomo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myomo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.